The driving forces that will define healthcare for investors in 2025

Market commentary of February 27, 2025

The driving forces that will define healthcare for investors in 2025

A wave of high-value acquisitions and groundbreaking medical advancements is setting the stage for a pivotal year in healthcare. With USD 250 bn in branded sales at risk, biopharma giants are racing to secure new assets, while medtech players actively pursue fast-growing market players. At the same time, game-changing obesity drugs, robotic surgery, and non-opioid pain treatments are hitting the market, creating fresh momentum. With capital flowing and science advancing, 2025 is poised to be a landmark year for investors.

Mergers and acquisitions are poised to become a defining force in the healthcare sector in 2025. With strong demand, ample capital availability, a stabilizing interest rate environment, and regulatory tailwinds, conditions are ripe for a surge in deal-making. M&A activity acts as a money-multiplier effect within the sector, unlocking capital from the balance sheets of large companies and channeling it into smaller innovators. The year has already started on a strong note, with Johnson & Johnson’s proposed USD 15 bn acquisition of Intra-Cellular in January, reinforcing the momentum for biotech deal-making in 2025.

M&A set to reshape the biopharma industry amid USD 1.3 tn capital surge
Within biopharma, approximately USD 250 bn* in branded sales are at risk over the next five years. These lost sales need to be replaced, with all major players identifying M&A as tool to meet this demand. Indeed, one-third** of the top-25 biopharma annual sales in 2023 were derived from prior M&A, underscoring the sector’s reliance on deal-making. Bringing in new programs and leveraging established sales and marketing platforms, can drive value in large biopharma. With approximately USD 1.3 tn in potential capital available for M&A, companies have ample resources to execute acquisitions, supported by strong balance sheets and the ability to raise debt**. Global interest rates have declined and are now stabilizing, providing a better environment for pricing innovation. Finally, we see a supportive regulatory environment under a new Trump administration Federal Trade Commission (FTC). We see M&A activity as important for driving biotech valuations.

Strong M&A momentum also in medtech
In medtech space, there were 48 M&A deals totaling USD 21 bn in 2024. The largest of these were the purchase of Shockwave by Johnson & Johnson (USD 12 bn), the sale of Edwards Lifescience's Critical Care business to Beckton Dickinson (USD 4.2 bn) and the acquisition of Axonics by Boston Scientific (USD 3.3 bn). Shockwave and Axonics are typical examples of large cap medtech companies acquiring innovative, faster-growing companies to accelerate sales growth and leverage their sales force.

We see the potential for an increase in M&A in the medtech sector in 2025 supported by a more favorable regulatory environment and normalized end-market growth rates. The most active strategic buyers in 2024 were Boston Scientific and Edwards Lifesciences, each with four acquisitions, while Johnson & Johnson, Zimmer Biomet and Stryker completed two deals each.

The momentum has continued into 2025 with Stryker acquiring Inari Medical (USD 4.6 bn), Zimmer Biomet buying Paragon 28 (USD 1.2 bn) and Boston Scientific acquiring Bolt Medical (USD 600 mn). All of these companies are likely to remain active throughout the year. In addition, we see Abbott and Medtronic potentially making some acquisitions. There was a trend towards more takeovers of listed companies in 2024 and we expect this trend to continue going forward.

_{Source: Nephron Research}

Innovations shaping 2025: Oral obesity drugs, non-opioid pain therapy, and next generation of robotic surgery
We expect oral pill obesity drugs to be a key focus in 2025. Key late-stage clinical trial data from Eli Lilly with orforglipron is expected in Q2 2025, along with US filing for approval of Novo Nordisk's oral semaglutide (oral version of Wegovy). Following behind, Pfizer could enter late-stage trials with oral danuglipron. While these oral treatments may result in lower weight loss compared to injectables, they offer a potentially more convenient mode of delivery, which we see as crucial for long-term maintenance therapy.

Beyond obesity, we will be closely monitoring the launch trajectory of Vertex Pharmaceuticals' newly approved pain drug, Journavx. This is a new novel mechanism of action in moderate-to-severe acute pain management, which we see as particularly important given the addictive qualities of the current stand-of-care opioids.

In medtech, the approval and subsequent launch of relevant new products will continue to support sales growth, driven by a sustained, above-average volume of surgical procedures compared to the pre-pandemic period, fueled by an aging population with improved access to healthcare.

The most influential new product cycle currently underway in 2025 is the full launch of da Vinci 5 robotic-assisted surgery system by Intuitive Surgical, followed by further strong growth of Boston Scientific's Farapulse in pulsed field ablation (PFA) for the treatment of atrial fibrillation to avoid diseases like stroke. In diabetes, Abbott is launching its wearable continuous glucose monitoring sensors Lingo, Libre Rio and Libre 3 plus, and Dexcom is commercializing G7 and Stelo for various patient groups.

In structural heart, Boston Scientific continues to generate momentum with the Watchman FLX Pro, a device for closing the left atrial appendage. Key new products being launched include Edward Lifescience's Evoque for tricuspid valve replacement and Abbott's TriClip system for tricuspid valve repair. Edwards’ Pascal Precision and Abbot's MitraClip both commercialize their mitral valve repair system. Edwards will launch the first commercial mitral valve replacement system Sapien M3 in Europe by mid-2025, with approval in the US expected in 2026. The clinical data for Sapien M3 will be presented at the TCT (Transcatheter Cardiovascular Therapeutics) conference in October.

Given the strong M&A momentum, notable medical innovations, and a favorable regulatory and economic backdrop, 2025 presents an attractive environment for healthcare investments. Investors can capitalize on these trends through actively managed, diversified portfolios, aligned with the sector’s key growth drivers.

*Evaluate, “The Patent Winter is Coming”, 25. Mai 2022

**EY M&A Firepower report, Januar 2025

Contact
Bellevue Asset Management AG, Theaterstrasse 12, 8001 Zurich,
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch, www.bellevue.ch
 

Bellevue – Excellence in Specialty Investments
Bellevue is a specialized asset manager listed on the SIX Swiss Exchange with core competencies covering healthcare strategies, entrepreneur strategies, alternative and traditional investment strategies. Established in 1993, Bellevue, a House of Investment Ideas staffed by 90 professionals, generates attractive investment returns and creates value added for clients and shareholders alike. Bellevue managed CHF 5.8 bn in assets as of December 31, 2024.

Disclaimer: This document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. The information and data presented in this document are not to be considered as an offer to buy or sell or an invitation to subscribe any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. Liability for the accuracy or completeness of all information in this document is expressly disclaimed. This information does not take into account the specific or future investment objectives, the financial or tax situation or the particular needs of any specific recipient. This document does not constitute independent investment research. Interested investors should always seek professional advice before making an investment decision. The information in this document is provided without any guarantees or warranties, for information purposes only, and is intended only for the personal use of the recipient. Every investment involves some risk, especially with regard to fluctuations in value and return. Investments in foreign currency involve the additional risk that a foreign currency might lose value against an investor's reference currency. This document does not reflect all possible risk factors associated with an investment in the aforementioned securities or financial instruments. Historical performance data and financial market scenarios are no guarantee or indicator of current and future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs adversely affect performance. Financial transactions should only be carried out after thorough study of the current prospectus and only on the basis of the most recently published prospectus and annual or semi-annual report. Bellevue Funds (Lux) SICAV is admitted for public distribution in Switzerland. Representative in Switzerland: Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne. Paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, P.O. Box, CH-8022 Zurich. Bellevue Funds (Lux) SICAV is admitted for public distribution in Austria. Paying and information agent: Zeidler Legal Process Outsourcing Limited, 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland. The Bellevue Funds (Lux) SICAV is admitted for public distribution in Germany. Information agent: Zeidler Legal Process Outsourcing Limited, SouthPoint, Herbert House, Harmony Row, Grand Canal Dock, Dublin 2, Ireland. Bellevue Funds (Lux) SICAV is registered in the CNMV registry of foreign collective investment schemes distributed in Spain, under registration number 938. Representative: atl Capital, Calle de Montalbán 9, ES-28014 Madrid. Prospectus, Key Investor Information Document (PRIIP-KIID), the articles of association as well as the annual and semi-annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above-mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Theaterstrasse 12, CH-8001 Zurich. With respect to fund units distributed in or from Switzerland, the place of performance and jurisdiction is established at the registered office of the representative.